Please wait





02/24/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  The figures in Items 6, 8, and 9 include (1) 135,354 shares of Common stock, $.01 par value per share ("Common Stock") of Haemonetics Corporation (the "Issuer") held directly by North Peak Capital Partners, LP, (2) 993,566 shares of Common Stock held directly by North Peak Capital Partners II, LP, (3) 651,061 shares of Common Stock held directly by North Peak Capital Alpha Fund, LP and (4) 102,056 shares of Common Stock held directly by North Peak Capital Ultra Fund, LP. The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025 filed with the U.S. Securities and Exchange Commission (the "Commission") on February 5, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The figures in Items 6, 8, and 9 include (1) 135,354 shares of Common Stock of the Issuer held directly by North Peak Capital Partners, LP, (2) 993,566 shares of Common Stock held directly by North Peak Capital Partners II, LP, (3) 651,061 shares of Common Stock held directly by North Peak Capital Alpha Fund, LP and (4) 102,056 shares of Common Stock held directly by North Peak Capital Ultra Fund, LP. The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The figures in Items 6, 8, and 9 include (1) 135,354 shares of Common Stock of the Issuer held directly by North Peak Capital Partners, LP, (2) 993,566 shares of Common Stock held directly by North Peak Capital Partners II, LP, (3) 651,061 shares of Common Stock held directly by North Peak Capital Alpha Fund, LP and (4) 102,056 shares of Common Stock held directly by North Peak Capital Ultra Fund, LP. The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The figures in Items 6, 8, and 9 include (1) 135,354 shares of Common Stock of the Issuer held directly by North Peak Capital Partners, LP, (2) 993,566 shares of Common Stock held directly by North Peak Capital Partners II, LP, (3) 651,061 shares of Common Stock held directly by North Peak Capital Alpha Fund, LP and (4) 102,056 shares of Common Stock held directly by North Peak Capital Ultra Fund, LP. The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026.


SCHEDULE 13G



 
North Peak Capital Management, LLC
 
Signature:/s/ Jeremy Kahan
Name/Title:Jeremy Kahan/Managing Member
Date:03/03/2026
 
North Peak Capital GP, LLC
 
Signature:/s/ Jeremy Kahan
Name/Title:Jeremy Kahan/Manager
Date:03/03/2026
 
North Peak Capital Partners, LP
 
Signature:/s/ Jeremy Kahan
Name/Title:Jeremy Kahan/Manager of North Peak Capital GP, LLC, its General Partner
Date:03/03/2026
 
North Peak Capital Partners II, LP
 
Signature:/s/ Jeremy Kahan
Name/Title:Jeremy Kahan/Manager of North Peak Capital GP, LLC, its General Partner
Date:03/03/2026
 
North Peak Capital Alpha Fund, LP
 
Signature:/s/ Jeremy Kahan
Name/Title:Jeremy Kahan/Manager of North Peak Capital GP, LLC, its General Partner
Date:03/03/2026
 
North Peak Capital Ultra Fund, LP
 
Signature:/s/ Jeremy Kahan
Name/Title:Jeremy Kahan/Manager of North Peak Capital GP, LLC, its General Partner
Date:03/03/2026
 
Michael Kevin Kahan
 
Signature:/s/ Michael Kahan
Name/Title:Michael Kahan
Date:03/03/2026
 
Jeremy Steven Kahan
 
Signature:/s/ Jeremy Kahan
Name/Title:Jeremy Kahan
Date:03/03/2026
Exhibit Information

Exhibit 99.1 Joint Filing Agreement (filed herewith)